Association of TNF-α and Fas gene promoter polymorphism with the risk of Kashin-Beck disease in Northwest Chinese population

Clinical Rheumatology

Volumn 31, Issue 7, 2012, Pages 1051-1057

  Zhao, Quan Ming ^a,b   Guo, Xiong ^a   Lai, Jiang Hua ^a   Tan, Wu Hong ^a   Wang, Wei Zhuo ^b   Dang, Xiao Qian ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b the Second Affiliated Hospital   (China)

Author keywords

Chinese; Fas; Kashin Beck disease; Restriction fragment length polymorphisms; TNF alpha

Indexed keywords

FAS ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN TISSUE; KASHIN BECK DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIGENS, CD95; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHINA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KASHIN-BECK DISEASE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863717547     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-1975-7     Document Type: Article

References (46)

1. Guo X (2008) Progression and prospect of etiology and pathogenesis of Kashin-Beck disease. J Xi'an Jiaotong Univ Med Sci 29:481-488
2. Tan J, Zhu W, Wang W, Li R, Hou S, Wang D et al (2002) Selenium in soil and endemic diseases in China. Sci Total Environ 284(1-3):227-235
3. Peng A, Wang WH, Wang CX, Wang ZJ, Rui HF, Wang WZ et al (1999) The role of humic substances in drinking water in Kashin- Beck disease in China. Environ Health Perspect 107(4):293-296
4. Yang JB (1995) Etiology of Kashin-Beck disease. Chin J Endemiol 14:201-204
5. Wang WZ, Guo X, Duan C, Ma WJ, Zhang YG, Xu P et al (2009) Comparative analysis of gene expression profiles between the normal human cartilage and the one with endemic osteoarthritis. Osteoarthr Cartil 17(1):83-90
6. Duan C, Guo X, Zhang XD, Yu HJ, Yan H, Gao Y et al (2010) Comparative analysis of gene expression profiles between primary knee osteoarthritis and an osteoarthritis endemic to Northwestern China, Kashin-Beck disease. Arthritis Rheum 62(3):771-780
7. Sun ZM, Ling M, Liu M, Zhang YG (2009) Expression of interleukin-1beta and tumor necrosis factor-alpha in the synovium and synovial fluid of patients with Kashin-Beck disease and osteoarthritis. Nan Fang Yi Ke Da Xue Xue Bao 29(1):5-8
8. Yang TF, Wang G, Tong W, Gong Q, Cheng Y (2001) Measurement of the bioactivity of interleukin and tumour necrosis factor in synovial fluid of Kashin-Beck disease. Int Orthop 25(3):162-163
9. Zhang BD, Guo X, Bai GL, Ping ZG, Zuo H, Ren FL et al (2004) The changes of nitric oxide, NO synthase and sFas/APO-1 in serum among the patients with Kashin-Beck disease. Chin J Endmiol 23(2):172-175, in Chinese
10. Guo X (2005) Molecular biological mechanism on chondronecrosis in cartilage with Kashine-Beck disease. J Xi'an Jiaotong Univ Med Sci 26(3):201-204
11. Wang SJ, Guo X, Zuo H, Zhang YG, Xu P, Ping ZG et al (2006) Chondrocyte apoptosis and expression of Bcl-2, Bax, Fas, and iNOS in articular cartilage in patients with Kashine Beck disease. J Rheumatol 33(3):615-619
12. Shi Y, Lu F, Liu X, Wang Y, Huang L, Liu X et al (2011) Genetic variants in HLA-DRB1 gene are associated with Kashin-Beck disease in the Tibetan population. Arthritis Rheum 63(11):3408-3416
13. Tian L, Wang W, Hou W, Tian J, Zhong N, Sun J et al (2011) Autoimmune and inflammatory responses in Kashin-Beck disease compared with rheumatoid arthritis and osteoarthritis. Hum Immunol 72:812-816
14. Lee JY, Kim HY, Kim KH, Kim SM, Jang MK, Park JY et al (2005) Association of polymorphism of IL-10 and TNF-A genes with gastric cancer in Korea. Cancer Lett 225(2):207-214
15. Hajeer AH, Hutchinson IV (2000) TNF-alpha gene polymorphism: clinical and biological implications.Microsc Res Tech 50(3):216-228
16. Yamada J, Streilein JW, Dana MR (1999) Role of tumor necrosis factor receptors TNFR-I (p55) and TNFR-II (p75) in corneal transplantation. Transplantation 68(7):944-949
17. Hussein YM, Mohamed RH, Pasha HF, El-Shahawy EE, Alzahrani SS (2011) Association of tumor necrosis factor alpha and its receptor polymorphisms with rheumatoid arthritis in female patients. Cell Immunol 271(1):192-196
18. Fernandes JC, Martel-Pelletier J, Pelletier JP (2002) The role of cytokines in osteoarthritis pathophysiology. Biorheology 39 (1-2):237-246
19. Sandell LJ, Aigner T (2001) Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res 3(2):107-113
20. Kaijzel EL, Brinkman BM, van Krugten MV, Smith L, Huizinga TW, Verjans GM et al (1999) Polymorphism within the tumor necrosis factor alpha (TNF) promoter region in patients with ankylosing spondylitis. Hum Immunol 60(2):140-144
21. Kim HA, Lee YJ, Seong SC, Choe KW, Song YW (2000) Apoptotic chondrocyte death in human osteoarthritis. J Rheumatol 27(2):455-462
22. Liu H, Pope RM (2003) The role of apoptosis in rheumatoid arthritis. Curr Opin Pharmacol 33(3):317-322
23. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X (1999) Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15:269-290
24. Nagata S (1997) Apoptosis by death factor. Cell 88:355-365
25. Muschen M, Warskulat U, Beckmann MW (2000) Defining CD95 as a tumor suppressor gene. J Mol Med (Berl) 78(6):312-325
26. Huang QR, Morris D, Manolios N (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34(8-9):577-582
27. Shuai K (1994) Interferon-activated signal transduction to the nucleus. Curr Opin Cell Biol 6(2):253-259
28. Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J et al (2002) A functional polymorphism in Fas (CD95/Apo-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 29(6):1183-1188
29. Hashimoto S, Setareh M, Ochs RL, Lotz M (1997) Fas/Fas ligand expression and induction of apoptosis in chondrocytes. Arthritis Rheum 40(10):1749-1755
30. Huang QR, Danis V, Lassere M, Edmonds J, Manolios N (1999) Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatol (Oxford) 38(7):645-651
31. Shi XW, Guo X, Ren FL, Lu AL, Zhang YZ (2008) Familial aggregation and sibling heritability in Kashin-Beck disease. Nan Fang Yi Ke Da Xue Xue Bao 28(7):1187-1189
32. Ping ZG, Guo X, Wang FQ, Wang ZW (2004) Epidemiological characters of Kashin-Beck disease in nuclear families (in chinese). Chin J Epidemiol 25(10):848-851
33. Xiong YM, Mo XY, Zou XZ, Song RX, Sun WY, Lu W et al (2010) Association study between polymorphisms in selenoprotein genes and susceptibility to Kashin-Beck disease. Osteoarthr Cartil 18(6):817-824
34. Y U M, Guo X, Gao XY, Lai JH, Tu QQ (2010) Association between polymorphism in DVWA and IL-1beta and Kashin- Beck disease. Sichuan Da Xue Xue Bao Yi Xue Ban 41:669-673
35. Xiong G (2001) Diagnostic, clinical and radiological characteristics of Kashin-Beck disease in Shaanxi Province, PR China. Int Orthop 25(3):147-150
36. Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A et al (2005) G-308A TNF-a polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun 334(2):588-592
37. Beutler B, Bazzoni F (1998) TNF apoptosis and autoimmunity: a common thread? Blood Cells Mol Dis 24(2):216-230
38. Kroeger KM, Steer JH, Joyce DA, Abraham LJ (2000) Effects of stimulus and cell type on the expression of the -308 tumour necrosis factor promoter polymorphism. Cytokine 12 (2):110-119
39. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56(4):549-580
40. Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2(5):364-371
41. Goldring MB (2000) Osteoarthritis and cartilage: the role of cytokines. Curr Rheumatol Rep 2(6):459-465
42. Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA et al (1997) TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 72(2):149-153
43. Donn R, Zeggini E, Shelley E, Ollier W, Thomson W, British Paediatric Rheumatology Study Group (2002) Lack of association between juvenile idiopathic arthritis and fas gene polymorphism. J Rheumatol 29(1):166-168
44. Huang QR, Danis V, Lassere M, Edmonds J, Manolios N (1999) Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 38(7):645-651
45. Xia B, Yu YH, Guo QS, Li XY, Jiang L, Li J (2005) Association of Fas -670 gene polymorphism with inflammatory bowel disease in Chinese patients. World J Gastroenterol 11(3):415-417
46. Stuck BJ, Pani MA, Besrour F, Segni M, Krause M, Usadel KH et al (2003) No association of two Fas gene polymorphisms with Hashimoto's thyroiditis and Grave's disease. Eur J Endocrinol 149 (5):393-396